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Abstract
Introduction Breast carcinomas associated with pregnancy
display a high frequency of inflammatory types, multifocal lesions
and lymph node metastasis. Because pregnancy results in
transfer to mothers of foetal stem cells that can migrate and
differentiate into various tissues, we addressed the issue of
whether such cells are present in breast carcinoma associated
with pregnancy.
Methods We analyzed women presenting with such tumours
who were pregnant with male foetuses using fluorescence in
situ hybridization (FISH), targeting X and Y chromosomes. The
foetal cell phenotype was then determined by combining FISH
and immunohistochemistry with various antibodies. Statistical
analysis was performed using t-test or nonparametric
Wilcoxon's test.
Results We found that foetal cells were present in nine out of
10 carcinomas, in contrast with none of four benign mammary
lesions (P < 0.05). Counting foetal and maternal cells showed
that the mean number of foetal cells per million maternal cells
was 36 in breast cancers and 0 in control samples (P < 0.01).
By combining FISH and immunolabelling, we found that foetal
cells expressed mainly mesenchymal or, to a lesser degree,
epithelial or endothelial markers, but never leucocytes.
Conclusion These findings demonstrate the frequent presence
of foetal derived cells essentially in tumour stroma. Given the
role played by stroma in tumour proliferation, these findings raise
the issue of whether foetal cell can be targeted to influence
tumour behaviour.
Introduction
Breast cancer is among the two most commonly diagnosed
cancers of pregnancy, along with cervical cancer [1]. Up to
3.8% of all breast carcinomas are associated with pregnancy
[2]. These tumours account for 8% of breast cancers occur-
ring in women younger than 45 years old and for as many as
18% of women younger than 30 years [2]. One of the most
used definitions of pregnancy-associated breast carcinoma
(PABC) emphasizes the fact that these tumours develop dur-
ing pregnancy itself or during the first year after delivery [1,3].
Accordingly, analysis of the literature shows that PABC devel-
ops in 60% of patients during pregnancy itself and 40% of
cases occurred during the year following delivery [4]. In addi-
tion, these tumours appear to exhibit peculiar profiles of evolu-
tion. Indeed, 14% to 28% of PABCs are of inflammatory types
[5]. These tumours were found to be significantly larger, with
more extensive lymph node involvement, as compared with
tumours developing in nonpregnant women [6]. Finally, the
SBR (Scarff, Bloom, Richardson; a histological index) grades
of PABCs appear to be high [6,7].
Pregnancy induces the transfer of foetal cells that may persist
for decades in the mother. Foetal transferred cells include dif-
ferentiated cells as well as several progenitor cell types, such
as haematopoietic [8] and mesenchymal stem cells [9]. These
progenitors are capable of migration in maternal damaged tis-
sues and can differentiate into various phenotypes [10]. Sev-
eral groups have suggested that microchimeric foetal cells
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were recruited to maternal lesional tissues such as kidney,
liver, or brain tissues in order to help in the repair process, and
may rescue genetically deficient maternal tissues [11-13].
Similarly, we recently demonstrated the ability of foetal
endothelial progenitor cells to form blood vessels in maternal
inflamed skin [14].
Microchimeric cells have also been detected in tumours.
Indeed, in a series of kidney transplant recipients, we and oth-
ers recently reported that epidermal skin carcinoma and, more-
over, Kaposi's sarcomas may arise from microchimeric donor
cells [15]. Similarly, nontumoural cytokeratin-expressing foetal
microchimeric cells have been identified in cervical cancer
from women with a prior history of pregnancy [16].
Because PABC appears to be a frequent condition with an
aggressive course, and because foetal cells can participate in
tissue remodelling, we conducted the present study to analyze
the presence and phenotype of foetal cells in PABCs.
Materials and methods
Materials
We retrospectively retrieved data from two institutions (Institut
Gustave Roussy and Hôpital Tenon) between 2000 and
2005. In order to be eligible for inclusion, female patients had
to fulfill the following criteria: pathologically proven ductal
breast carcinoma; carcinoma diagnosed during pregnancy or
during the 6 months after delivery; male child; and availability
of formalin fixed paraffin-embedded specimens (biopsy,
tumourectomy, or mastectomy). The study fulfilled the commit-
ments of ethics regulations in France in terms of institutional
review board approval and informed consent. Ten cases were
identified; six had neoadjuvant chemotherapy and four had
adjuvant chemotherapy. Control samples included benign
breast tumour, such as fibroadenosis and mastosis, obtained
from women pregnant with a male baby. The samples were
made available to us in accordance with national and Euro-
pean procedures and ethical guidelines.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed to
detect male foetal cells in maternal breast, as was previously
described by Johnson and coworkers [17], in 5 μm thick par-
affin-embedded sections. We used X and Y chromosome
probes labelled respectively with Cy3 (red) and FITC (green),
mapping to Xp11.1q11.1 (a satellite centromeric region of the
X chromosome) and to Yq12 (satellite III region of the Y chro-
mosome; Abbott, Chicago, IL, USA).
FISH combined with immunostaining (immuno-FISH)
In order to determine the phenotype of foetal cells detected in
the sections of breast carcinomas associated with pregnancy,
we combined X and Y FISH with immunostaining. This was
done in similar 5 μm thick paraffin-embedded sections, as was
previously described [10,18]. The antibodies were anti-CD45
(monoclonal mouse anti-human CD45, clone 2B11 + PD7/
26; Dako, Carpintera, CA, USA), anti-CD34 (monoclonal
mouse anti-human CD34 class II, clone QBEnd-10; Dako),
anti-vimentin (monoclonal mouse anti-vimentin, clone Vim
3B4; Dako) and anti-cytokeratin (monoclonal mouse anti-
human cytokeratin, clone AE1/AE3; Dako), which stain leuco-
cytes, endothelial cells, stromal cells and epithelial cells,
respectively. For the FISH combined with anti-CD34 and anti-
CD45 antibody labelling, we used the Envision + peroxidase
kit (Dako). For FISH combined with anti-cytokeratin and anti-
vimentin labelling, we used an immunofluorescence technique
with secondary goat anti-mouse antibody labelled with Texas
red (Jackson immunoresearch, West Grove, PA, USA). All
slides were counterstained with 4',6-diamidino-2-phenylin-
dole.
Scoring and statistical analysis
Sections of tissue from female pregnant patients and control
sections were all analyzed for the presence of male (presuma-
bly foetal) cells. Sections were scored if more than 70% of the
nuclei had at least one FISH signal. Male cells were recog-
nized as having one X (red) and one Y (green) chromosome
within an intact blue-stained nucleus. We estimated the total
number of nucleated cells in each section by counting the
number of nuclei in six fields that were randomly chosen (630×
magnification). The size of our samples in case and control
groups was identical and a total of 6 million cells were evalu-
ated in all samples combined (range 10e5 to 2 × 10e6).
For each case, the number of foetal cells found was reported
as the total number of cells examined. The frequency of foetal
cells and the proportion of tumours with foetal cells were then
compared between the breast carcinomas and the control
group using Student's t-test or nonparametric Wilcoxon's test.
Results
Patient characteristics
During the study period, more than 5,000 women were diag-
nosed with breast carcinomas in the two institutions. Sixty
patients developed breast carcinoma during pregnancy or dur-
ing the 6 months after delivery; only 10 had tumours that cor-
responded with the inclusion criteria. The clinical and
histological characteristics of the patients and their breast
tumours are summarized in Table 1. No patient or control indi-
vidual had a history of blood transfusion, organ transplantation,
or a twin sibling that could have been a confounding factor in
interpreting male cell microchimerism. The mean ages of the
patients and control individuals were 36 years (range 27 to 40
years) and 35 years (range 30 to 40 years), respectively.
Among the malignant lesions, five were diagnosed during
pregnancy at a median term of 7 months (range 2 to 7
months), and five were diagnosed postpartum at a median
delay of 4 months. The four benign lesions were all diagnosed
during pregnancy at a median term of 4 months (3 to 6
months). The median sizes of the malignant tumours andAvailable online http://breast-cancer-research.com/content/10/1/R14
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benign lesions were 36 mm (range 5 to 80 mm) and 28 mm
(range 22 to 70 mm), respectively.
The analyzed specimens consisted of four tumourectomies,
five mastectomies and five biopsies (four benign lesions and
one carcinoma).
Detection of foetal cells
We detected X and Y positive foetal cells in maternal tumoural
tissues in nine out of 10 ductal carcinomas versus none of four
breast adenofibroma or mastosis samples (P < 0.01) (Table
2). The unique PABC that did not exhibit foetal cells was a
small biopsy specimen. Surgical samples contained healthy
and breast carcinoma tissue. Microchimeric cells were distrib-
uted throughout the specimens and were preferentially
located in tumoural area rather than nontumoural areas. Mor-
phologically, they were undistinguishable from the surround-
ing cells in terms of size and nuclear shape. Of note, the foetal
cells were never grouped in clusters. We estimated the fre-
quency of the foetal cells; we found an average of 19 foetal
cells per million maternal cells (median frequency: 20 fetal/mil-
lion maternal cells) versus none per million maternal cells in
control individuals (P < 0.01; Figure 1). In addition, we com-
pared the level of faetal cells according to patient features.
There were fewer foetal cells in patients who had received
neoadjuvant chemotherapy than in those who were not treated
(23 versus 56 foetal cells/million maternal cells), but the differ-
ence did not reach statistical significance. No relationship
were established between timing of surgery (during versus
after pregnancy), hormone receptor status, lymph node inva-
sion and number of foetal cells.
Phenotype of foetal cells
We next determined the phenotype of foetal cells in maternal
breast tumours according to four different markers. We used
CD45 to identify leucocytes, CD34 for endothelial cells, and
cytokeratin and vimentin for epithelium and stroma, respec-
tively (Table 2). In the 135 foetal cells that were identified and
Table 1
Clinical and histological characteristics of the patients and breast tumours
Patients/
control 
individuals
Time of 
diagnosis
Term of
diagnosis
(months)
Neoadjuvant 
chemotherapy
pTNM Size
(mm)
Nodal 
status
Histology Grade Estrogen 
receptors
Presence 
of MC 
cells
Number 
of MC 
cells
Number 
of MC 
cells/
10e6 
maternal 
cells
Patients
1 Pregnancy 2 Yes T3N0 60 3N+ Ductal 
carcinoma
31 P o s i t i v e 1 6 8
2 Pregnancy 7 Yes T4N0 4 6 15N-/15 Ductal 
carcinoma
30 P o s i t i v e 2 0 7 8
3 Postpartum 6 No T2N0 25 11N- Ductal 
carcinoma
30 P o s i t i v e 3 7
4 Pregnancy - No T3N1 30 14N+ Ductal 
carcinoma
30 P o s i t i v e 2 3 2 4
5 Postpartum 4 No T2N1 27 2N+ Ductal 
carcinoma
31 P o s i t i v e 1 7 1 6 5
6 Postpartum 3 No T2N1 5 24N- Ductal 
carcinoma
11 P o s i t i v e 1 9 2 9
7 Pregnancy 7 Yes T4D N3 80 24N+ Ductal 
carcinoma
30 P o s i t i v e 2 1 1 6
8 Postpartum 5 Yes T3N1 70 6N+ Ductal 
carcinoma
21 P o s i t i v e 6 1 2
9 Postpartum 1 Yes T2N1 40 13N- Ductal 
carcinoma
21 P o s i t i v e 1 0 2 6
10 Pregnancy 7 Yes T2N1 36 N+ Ductal 
carcinoma
31 N e g a t i v e 0 0
Controls
1 Pregnancy 4 - - 70 - Mastosis - - Negative 0 -
2 Pregnancy 4 - - 28 - Fibroadenosis - - Negative 0 -
3 Pregnancy 4 - - 28 - Fibroadenosis - - Negative 0 -
4 Pregnancy 4 - - 22 - Fibroadenosis - - Negative 0 -
MC, microchimericBreast Cancer Research    Vol 10 No 1    Dubernard et al.
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evaluated individually for phenotype, vimentin expression and
cytokeratin expression were identified in 22% (2/9 microchi-
meric cells) and 16% (12/74 microchimeric cells), respec-
tively (Figure 2). CD34 expression was found in only one out
of 20 analyzed foetal cells (5%). Foetal cells never expressed
CD45.
Discussion
This study was conducted to determine whether there is an
interaction between a tumour type that is known to develop
during pregnancy and foetal cells, which can migrate and dif-
ferentiate in various maternal tissues. Our findings show that
among women bearing a child, only those with breast carci-
noma had foetal cells in their mammary tissue. Although the
number of specimens analyzed was low, significant differ-
ences from benign control samples were identified; moreover,
breast carcinomas nearly always had foetal cells within
tumoural areas.
PABC is usually defined as occurring during pregnancy, lacta-
tion and up to 1 year after delivery [1,3]. In this study, in order
to improve the stringency of detecting PABC and to avoid
coincident cases, we restricted our sampling to tumours
occurring up to 6 months after delivery. In our view, this
allowed us also to avoid other unknown factors that may inter-
fere with foetal cell trafficking over a prolonged period and to
focus on a period characterized by higher levels of circulating
foetal cells. Depending on country, breast carcinomas are the
first or the second most common cancer occurring in pregnant
women [1]. It develops in about one in 3,000 pregnant women
and therefore represents a troublesome but not infrequent dis-
ease [19]. The profile of breast cancer during pregnancy has
a number of distinct features. Women with PABC have larger
tumours and with lymph node invasion occurring in 56% to
89%, as compared with 38% to 54% in breast carcinomas not
associated with pregnancy [3,5,6,20-25]. Similarly, women
with PABC were more likely to have tumours of high histolog-
ical grade, to exhibit a high level of mitosis, and to be proges-
terone receptor negative than matched nonpregnant control
women [26,27]. However, in two studies [24,28], when
patients and nonpregnant control women were matched for
histological grade and tumour stage, survival rates were equiv-
alent. Therefore, the poorer scores of PABCs may result from
a more advanced stage at diagnosis, because physiological
changes in the breast delay diagnosis [23,29-32]. Alterna-
tively, these higher scores may reflect an intrinsically worse
profile for these breast carcinomas.
Analysis of the precise types of infiltrating foetal cells, which
were present at very low levels, proved difficult. Although our
team has accumulated experience in combining FISH and
immunolabelling, each antibody in various tissues required
careful evaluation, with multiple preliminary trials. Because this
multistep, delicate technique was applied to few cells, only
Table 2
Level of foetal cells observed in breast carcinoma and in control group
Patients/control individuals Presence of MC cells Number of MC cells Number of MC cells/10e6 
maternal cells
Cytokeratin CD34 CD45 Vimentin
Patients
1 P o s i t i v e 1 6 8 4 00-
2 P o s i t i v e 2 0 7 8 0 00-
3 P o s i t i v e 3 7 0 00-
4 P o s i t i v e 2 3 2 4 1 000
5 P o s i t i v e 1 7 1 6 5 1 00-
6 P o s i t i v e 1 9 2 9 4 00-
7 P o s i t i v e 2 1 1 6 0 002
8 P o s i t i v e 6 1 2 1 00-
9 P o s i t i v e 1 0 2 6 1 10-
1 0 N e g a t i v e 0 0 - ---
Controls
1N e g a t i v e 0 -
2N e g a t i v e 0 -
3N e g a t i v e 0 -
4N e g a t i v e 0 -
MC, microchimeric.Available online http://breast-cancer-research.com/content/10/1/R14
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40% of total foetal cells could be identified with precision,
which is in accordance with our usual findings under such cir-
cumstances. Foetal cells in the vicinity of breast carcinomas
were not circulating leucocytes nor endothelial cells, but
seemed mainly of mesenchymal or epithelial origin, because
these expressed vimentin or cytokeratin, respectively.
Because the foetal cells that we identified were isolated and
not organized as clusters, they were not part of the neoplastic
clone, even if they expressed antigens that can be found within
the adenocarcinoma.
Pregnancy induces the transfer of foetal haematopoietic, mes-
enchymal and endothelial stem cells to the mothers. These
may persist decades after delivery in niches such as the
mother's bone marrow. The persisting foetal stem cells may
interact with maternal peripheral tissues. Indeed, several
human and murine studies have demonstrated that foetal
derived cells were present in thyroid, intestinal liver, neuronal,
glial [12] and kidney tubular cells [11]. Interestingly, most
studies have demonstrated that these foetal derived cells
home to lesional tissues, where they adopt the phenotype of
the affected tissues [11,13,33]. Therefore, it appears that foe-
tal cells are recruited in damaged organs, where they differen-
tiate or fuse with host cells to adopt the phenotype of the
involved tissue.
In the present study, we describe foetal derived cells express-
ing fibroblast, epithelial and even endothelial markers in breast
carcinomas. These findings are in accordance with the above-
mentioned previous studies and demonstrate that the stroma
of malignant tumours developing during pregnancy nearly
always recruits foetal derived cells. In mice as well as in
humans, CD34 haemopoietic progenitors may develop into
isolated epithelial cells without clusters in injured tissues, sim-
ilar to our findings [34,35]. Mesenchymal stem cells can be
recruited by cancer tissue, as was previously described [36].
More recently, we reported the observation that endothelial
progenitor cells of foetal origin could form blood vessels in
maternal inflammatory skin during pregnancy [14]. All of these
data can therefore account for the presence of foetal fibrob-
lasts, and endothelial and epithelial cells in breast carcinomas.
Although, Cha and coworkers [16] in cervical carcinomas in
women with a prior history of pregnancy reported the pres-
ence of CD45+ leucocytes in 44.4% but also cytokeratin foetal
derived cells in 24.3%. The present study is the first system-
atic evaluation of foetal cell invasion in carcinomas developing
during or shortly after pregnancy. We previously conducted a
study of skin epithelial tumours in skin cancers developing
after kidney transplantation, a situation similar to pregnancy
because it is characterized by the presence of a small number
Figure 1
Frequency of foetal cells Frequency of foetal cells per million of maternal cells in breast carcinoma and in control group.Breast Cancer Research    Vol 10 No 1    Dubernard et al.
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of circulating donor cells [15]. In that context, microchimeric
cells from the donors were frequently found in cutaneous
malignant epithelial tumours, but they were not epithelial [15].
In a unique and peculiar case, such donor cells were even able
to give rise to a skin carcinoma, a situation that we did not
identify in the present study. Interestingly, Kaposi's sarcoma in
kidney transplant recipients occured more frequently in donor
tissue [37]. However, these tumours are not epithelial but
derive partly from endothelial cells. Endothelial progenitors cir-
culate and may therefore have been present in the trans-
planted kidney. Therefore, malignancies occurring during
pregnancy appear to frequently recruit foetally derived cells
Figure 2
Photomicrographs showing male cells Photomicrographs showing male cells with X (red) and Y (green) chromosome signals within breast carcinoma after fluorescence in situ hybridiza-
tion (FISH). (a,b) Male cells after FISH (arrows). Original magnifications: 630× for panel a and 1,000× for panel b. (c,d) A cluster of cytokeratin-pos-
itive cells: panel c shows male cells after FISH in a cluster of maternal cells (arrow), and panel d shows cytokeratin-positive male cell after FISH and 
immunolabelling (arrow). Original magnification: 1,000× for both panels. (e,f) A cluster of vimentin-positive cells: panel e shows a male cell after 
FISH in a cluster of maternal cells (arrow), and panel f shows a vimentin-positive male cell after immunolabelling (arrow). Original magnification: 
1,000× for both panels.Available online http://breast-cancer-research.com/content/10/1/R14
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and, in the case of breast, these are mainly cells stroma partic-
ipating. Gadi and Nelson [38] recently found that detection of
foetal cells occurred more frequently in peripheral blood from
women without breast carcinomas than in those presenting
with breast cancer. These authors therefore suggest that cir-
culating foetal microchimerism could 'protect' women from
developing breast carcinoma [38].
Pregnancy associated carcinomas are aggressive tumours.
Our small series of 10 patients suggests that PABC is charac-
terized by the presence of foetal cells in stroma. Stroma may
influence tumor cell proliferation and may eventually be rele-
vant to prognosis [39]. This observation is potentially impor-
tant enough to warrant further investigation. Indeed, foetal
derived stromal cells may behave in a different way from adult
maternal cells, because foetal mesenchymal cells exhibit a
greater degree of plasticity, grow more rapidly and exhibit
longer telomers than do their adult counterparts [40]. In addi-
tion, the maternal immune system allows fetal cells bearing
paternal nonshared antigens to avoid immune responses.
Human leucocyte antigen (HLA)-G is among the molecules
that are expressed by foetal cells to reduce maternal immune
responses [41]. HLA-G abnormal expression has also been
suspected of playing a role in various malignancies, including
breast cancer [42]. One can therefore hypothesize that foetal
cells in breast cancer tumours may influence tumour evolution.
However, this question should be addressed through compar-
isons of foetal cell infiltration between PABC and similar
tumours occurring years or decades postpartum.
Conclusion
The presence of foetal cells in PABC is a frequent phenome-
non. These cells were mostly part of the tumour stroma and
could intervene in the poorer profile of these carcinomas.
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